InSysBio to take part in PharmSci360 2021

events
Conference
August 2, 2021

August 2, 2021

InSysBio announces its participation in AAPS 2021 PHARMSCI 360 which is to be held in Pennsylvania Convention Center, Philadelphia, PA, and Online 17-20 October, 2021. InSysBio team is going to present the update at the Virtual Booth (VB1) and 2 posters in frames of the Conference, namely:

Monday, October 18, 202112:30 PM – 1:30 PM ET:

Wednesday, October 20, 202112:30 PM – 1:30 PM E

Visit our Virtual Booth (VB1) and follow our presenters!

The news is going to be updated.

About InSysBio

InSysBio is a Quantitative Systems Pharmacology (QSP) company located in Moscow, Russia (INSYSBIO LLC) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 120 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit www.insysbio.com.

November 2019
MoTuWeThFrSaSu
    
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
1. 18 Nov 2019 19:58 Course “Modeling for systems biology and biomedicine” at the Faculty of Bioengineering and Bioinformatics This year InSysBio CEO Dr Oleg Demin with expert modelers Tatiana Karelina and Evgeny Metelkin and modelers Dmitry Shchelokov, Svetlana Rubina and Veronika Musatova are giving the course “Modeling for systems biology and biomedicine” at the Faculty of Bioengineering and Bioinformatics, Lomonosov Moscow State University.
19
20
21
22
23
24
25
1. 25 Nov 2019 18:47 PK/RO simulator for anti-PD-1 mAbs InSysBio, a pioneer in Quantitative Systems Pharmacology (QSP), modeling and simulation for drug development, announced the launch of application ‘PK/RO simulator for anti-PD-1 mAbs’. The application is based on the model allowing to predict pharmacokinetics and target binding in human for therapeutic antibodies against PD-1 receptor.
26
27
28
29
30
 
Upcoming Events
Tags
Latest News
25.06
InSysBio to announce extension of collaboration with discoveric bio alpha
18.06
InSysBio to publish the new article in CPT: Pharmacometrics & Systems Pharmacology
03.06
InSysBio to present Integration of Cytocon DB and fIVE DB with Heta for QSP modeling
30.05
InSysBio to publish the new article in CPT: Clinical Pharmacology & Therapeutics
15.05
15th InSysBio’s Annual Internal Scientific Meeting